Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465747 | 1.00 | PYCR1 (0.46) | PYCR1DGAT1PDPK1PTGDR2KDM1A | |
| SCHEMBL5826 | 0.83 | PDPK1 (0.48) | PYCR1DGAT1PDPK1KDM1AAKR1B1 | |
| SCHEMBL135165 | 0.82 | PTGDR2 (0.49) | DGAT1PTGDR2HSD17B10MEN1KMT2A | |
| SCHEMBL8828 | 0.79 | CA2 (0.54) | PYCR1DGAT1PDPK1KDM1AAKR1B1 | |
| SCHEMBL20465750 | 0.79 | PYCR1 (0.47) | PYCR1DGAT1PDPK1KDM1AAKR1B1 | |
| SCHEMBL308050 | 0.79 | PYCR1 (0.47) | PYCR1DGAT1PDPK1KDM1AAKR1B1 | |
| SCHEMBL11918441 | 0.79 | ALOX15 (0.46) | PTGDR2CYP1A2CYP2C9 | |
| SCHEMBL15806743 | 0.79 | PYCR1 (0.47) | PYCR1DGAT1PDPK1KDM1AAKR1B1 | |
| SCHEMBL31448605 | 0.79 | PYCR1 (0.47) | PYCR1DGAT1PDPK1KDM1AAKR1B1 | |
| SCHEMBL30380405 | 0.79 | ALOX15 (0.46) | PTGDR2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12509423-B2 | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | ALCHEMEDICINE, INC. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| US-6452056-B1 | REDUCING FLUORINATED BENZONITRILE TO A BENZYLAMINE WHICH IS REPLACED WITH A HYDROXYL GROUP | ASAHI GLASS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| CN-1349963-A | Direct method of reducing sodium bisuflite affixture of adhehyde or methyl ketone into correspondent alcohol | SHANGHAI INST ORGANIC CHEM (CN) | 2002-05-22 | — | — | CN | disclosed |
| CN-1077095-C | Preparation method of p-fluorophenol | BROMINE COMPOUNDS LTD (IL) | 2002-01-02 | — | — | CN | disclosed |
| CN-1312783-A | Process for preparing fluorobenzyl derivatives | ASASHI GLASS CO (JP) | 2001-09-12 | — | — | CN | disclosed |
| EP-1114809-A1 | PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES | Asahi Glass Co., Ltd. (JP) | 2001-07-11 | — | — | EP | disclosed |
| CN-1208398-A | Preparation method of p-fluorophenol | BROMINE COMPOUNDS LTD (IL) | 1999-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | PYCR1 1128/4885DGAT1 1327/4885PDPK1 334/4885 |
| US-12509423-B2 | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | ALDH2, ALDH1A1, ADH1A | PYCR1 1612/4885DGAT1 352/4885PDPK1 1231/4885 |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | PYCR1 1671/4885DGAT1 1377/4885PDPK1 371/4885 |
| US-20260049092-A1 | ANTIBACTERIAL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, FPR1 | PYCR1 64/4885DGAT1 948/4885PDPK1 3421/4885 |
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | PYCR1 1188/4885DGAT1 2449/4885PDPK1 2550/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | PYCR1 3790/4885DGAT1 1528/4885PDPK1 1059/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | PYCR1 3654/4885DGAT1 1768/4885PDPK1 1155/4885 |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | PYCR1 2651/4885DGAT1 2748/4885PDPK1 816/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | PYCR1 2907/4885DGAT1 598/4885PDPK1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.